Neonatal screening or Newborn Screening involves the screening of newborns in the first days of their lives for inborn errors of metabolism and certain disorders that can hinder the normal development of the baby. These disorders, are not apparent at the time of the baby's birth, but have potential to cause permanent neurological, cognitive, tactile and physical damage in the child. Early detection of such diseases enable initiating of suitable interventions to prevent concerning conditions in the long run. Trivitron provides a wide range Newborn Screening instruments, including Modular & Fully Automated NBS Instrumentation, manual & automated equipment and reagent kits. Trivitron's Diagnostic division Labsystems Diagnostics OY occupies the second place in the world when it comes to New Born Screening Technology.
Labsystems Diagnostics' Neonatal 17-OH-Progesterone FEIA test is a fluorometric enzyme immunoassay enabling the quantification of 17-hydroxyprogestrone steroid present in blood samples dried on filter paper. The test can be used for the screening of newborn for Congenital Adrenal Hyperplasia (CAH).
Labsystems Diagnostics' Neonatal 17-OH-Progesterone FEIA test is a fluorometric enzyme immunoassay enabling the quantification of 17-hydroxyprogestrone steroid present in blood samples dried on filter paper. The test can be used for the screening of newborn for Congenital Adrenal Hyperplasia (CAH).